Publications

Calpro

Hamberg V, Wallman JK, et al | Rheumatol Int | 2023

Elevated fecal levels of the inflammatory biomarker calprotectin in early systemic sclerosis.

Hammer HB, Pedersen SL, et al | Scand J Clin Lab Invest | 2023

Calprotectin, a sensitive marker of inflammation, is robustly assessed in plasma from patients with early or established rheumatoid arthritis by use of different laboratory methods

Rojas Correa M, Estremera L, et al | Contemp Clin Trials Commun | 2023

DietaAnti-Inflamatoria or DAIN: A Crohn's disease management strategy tailored for Puerto Ricans

Blad N, Palmqvist R, Karling P. | BMC Cancer. | 2022

Pre-diagnostic faecal calprotectin levels in patients with colorectal cancer: a retrospective study.

Kim ES, Tarassishin L, Eisele C, et al | Gastroenterology | 2021

Longitudinal Changes in Fecal Calprotectin Levels Among Pregnant Women With and Without Inflammatory Bowel Disease and Their Babies.

Kolho KL, Alfthan H. | Scand J Gastroenterol. | 2020

Concentration of fecal calprotectin in 11,255 children aged 0-18 years.

Ankersen DV, Weimers P, et al | World J Gastroenterol. | 2019

Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial

Goll R, Heitmann R, et al | PLoS One | 2019

Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis.

Haisma SM, Galaurchi A, et al | PLoS One | 2019

Head-to-head comparison of three stool calprotectin tests for home use

Karling P, Lundgren D, et al |  Scand J Clin Lab Invest. | 2019

Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin.

Lundgren D, Eklöf V, et al | Scand J Gastroenterol | 2019

Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy.

Acevedo D, Salvador MP, et al |  J Clin Med Res. | 2018

Fecal Calprotectin: A Comparison of Two Commercial Enzymoimmunoassays and Study of Fecal Extract Stability at Room Temperature

Nation ML, Dunne EM, et al |  Sci Rep. | 2017

Impact of Lactobacillus reuteri colonization on gut microbiota, inflammation, and crying time in infant colic.

Kristensen V, Lauritzen T, et al | Clin Chem Lab Med | 2016

Patient-performed extraction of faecal calprotectin

Vinding KK, Elsberg H, et al | Inflamm Bowel Dis | 2016

Fecal Calprotectin Measured By Patients at Home Using Smartphones--A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease

Kristensen V, Klepp P, et al | J Crohns Colitis. | 2015

Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.

Kristensen V, Lauritzen T, et al | Scand J Clin Lab Invest | 2015

Validation of a new extraction device for measuring faecal calprotectin in inflammatory bowel disease, and comparison to established extraction methods

Soto-Méndez MJ, Romero-Abal ME et al | PLoS One | 2015

Associations among Inflammatory Biomarkers in the Circulating, Plasmatic, Salivary and Intraluminal Anatomical Compartments in Apparently Healthy Preschool Children from the Western Highlands of Guatemala

Prell C, Nagel D, et al |  BMJ Open. | 2014

Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study.

Burri E, Manz M, et al | Clin Chim Acta | 2013

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort.

Walkowiak J, Cofta S, et al | Eur Rev Med Pharmacol Sci | 2013

Phenylketonuria is not a risk factor for gut mucosa inflammation: a preliminary observation.

Komraus M, Wos H, Wiecek S, et al | Mediators Inflamm | 2012

Usefulness of faecal calprotectin measurement in children with various types of inflammatory bowel disease.

Complement

Balduit A, Bianco AM, Mangogna A, et al | Front Immunol | 2023

Genetic bases of C7 deficiency: systematic review and report of a novel deletion determining functional hemizygosity

Bulla R, Rossi L, Furlanis G, et al | Front Immunol | 2023

A likely association between low mannan-binding lectin level and brain fog onset in long COVID patients

Chow T, Shamszad P, Vinnard C, et al | Clin Transl Sci | 2023

First-in-human study with SAR445088: A novel selective classical complement pathway inhibitor.

Cîrciumaru A, Afonso MG, Wähämaa H, et al | Biomolecules | 2023

Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation

David Kavanagh, Larry A. Greenbaum, Arvind Bagga, et al | Kidney International Reports | 2023

Design and rationale of the APPELHUS Phase 3 open-label study of Factor B inhibitor iptacopan for atypical hemolytic uremic syndrome

Dieckmann R, Pullerits R, Bylund J, et al |  J Immunol Res | 2023

Antieosinophil Antibodies Alone or in Combination with Antineutrophil Cytoplasmic Antibodies (ANCA) Detected in Different Autoimmune Conditions

García-González M, Gómez-Bernal F, Quevedo-Abeledo JC, et al | Front Immunol. | 2023

Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

Gerber, GF, Pan, XZ, Lederman, HM et al |  J Clin Immunol | 2023

Novel Functional Assay to Characterize Mutations in Alternative Pathway of Complement.

Ikeda Z, Kamei T, Sasaki Y, et al | J Med Chem. | 2023

Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.

Kavanagh D, Greenbaum LA, Bagga A,et al | Kidney Int Rep | 2023

Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome

Rajagopal V, Leksa N, et al | Blood Adv | 2023

SAR443809: a selective inhibitor of the complement alternative pathway, targeting complement factor Bb.

Simmons KT, Chan J, et al | Clin Immunol | 2023

Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.

Simmons KT, Chan J, Hussain S, et al | Clin Immunol. | 2023

Anti-Citrullinated Protein Antibody Reactivity towards Neutrophil-Derived Antigens: Clonal Diversity and Inter-Individual Variation

Svärd A, Kastbom A, Ljungberg KR, et al | Front Immunol | 2023

Antibodies against Porphyromonas gingivalis in serum and saliva and their association with rheumatoid arthritis and periodontitis. Data from two rheumatoid arthritis cohorts in Sweden

Aghababa H, Ting YT, Pilapitiya D, et al | Virulence | 2022

Complement evasion factor (CEF), a novel immune evasion factor of Streptococcus pyogenes.

Garlich J, Cinier M, Chevrel A, et al | Biomolecules | 2022

Discovery of APL-1030, a Novel, High-Affinity Nanofitin Inhibitor of C3-Mediated Complement Activation.

Jaskowski TD, Martins TB, et al | J Clin Lab Anal | 2022

Comparison of four enzyme immunoassays for the detection of immunoglobulin G antibody against glomerular basement membrane

Kojima T, Inoue D, Wajima T, et al | Ren Fail | 2022

Circulating immune-complexes and complement activation through the classical pathway in myeloperoxidase-ANCA-associated glomerulonephritis

Breville G, Zamberg I, Sadallah S, et al | Front Immunol | 2021

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Willrich MAV, Ladwig PM, Martinez MA, et al | J Immunol Methods | 2021

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Bartoszek D, Mazanowska O, Kościelska-Kasprzak K, et al | Arch Immunol Ther Exp | 2019

Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays.

Fridkis-Hareli M, Storek M, Or E, et al | Mol Immunol | 2019

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models

Bartoszek D, Mazanowska O, Kościelska-Kasprzak K, et al | Transplant Proc | 2018

Functional Activity of the Complement System in Deceased Donors in Relation to Kidney Allograft Outcome

Bjerre A, Bergseth G, Ludviksen JK, et al | Case Rep Nephrol. | 2018

Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome

Høiland II, Liang RA, Hindberg K, et al | Thromb Res | 2018

Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism

Lung T, Matozan K, Risch M, et al | Diagnosis (Berl) | 2018

Complement systems C4, C3 and CH50 not subject to a circadian rhythm

Willrich MAV, Andreguetto BD, Sridharan M, et al | J Immunol Methods | 2018

The impact of eculizumab on routine complement assays

Poppelaars F, Damman J, de Vrij EL, et al | Clin Exp Immunol | 2016

New insight into the effects of heparinoids on complement inhibition by C1-inhibitor

Volokhina EB, van de Kar NC, Bergseth G, et al | Clin Immunol | 2015

Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome

Cugno M, Gualtierotti R, et al | J Thromb Haemost | 2014

Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome

Korir JC, Nyakoe NK, et al | PLoS One. | 2014

Complement activation by merozoite antigens of Plasmodium falciparum

Roos A, Wieslander J. | Methods Mol Biol | 2014

Evaluation of complement function by ELISA

Inoshita H, Ohsawa I, Kusaba G, et al | BMC Nephrol | 2010

Complement in patients receiving maintenance hemodialysis: functional screening and quantitative analysis

Orth D, Ehrlenbach S, Brockmeyer J, et al | Infect Immun | 2010

EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5

Salvesen B, Mollnes TE. | Mol Immunol | 2009

Pathway-specific complement activity in pigs evaluated with a human functional complement assay

Ito-Ihara T, Muso E, Kobayashi S, et al | Clin Exp Rheumatol | 2008

A comparative study of the diagnostic accuracy of ELISA systems for the detection of anti-neutrophil cytoplasm antibodies available in Japan and Europe

Varga L, Széplaki G, Laki J, Kocsis A, et al | Clin Exp Immunol | 2008

Depressed activation of the lectin pathway of complement in hereditary angioedema

Csernok E, Holle J, Hellmich B, et al | Rheumatology (Oxford) | 2004

Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study

Villalta D, Tonutti E, Tampoia M, et al | Clin Chem Lab Med | 2004

Analytical and diagnostic accuracy of the EliA automated enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection

Segelmark M, Phillips BD, Hogan SL, et al | Clin Diagn Lab Immunol | 2003

Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis

Wieslab Diagnostic Services

Holzinger JM, Toelge M, Werner M, et al | Elife | 2023

Scorpionfish BPI is highly active against multiple drug-resistant Pseudomonas aeruginosa isolates from people with cystic fibrosis

Kosek S, Persson B et al. | Acta Scan | 2023

Antibody-Positive Autoimmune Encephalitis and Paraneoplastic Neurological Syndrome: Epidemiology and Outcome of Neuronal Antibody Testing in Sweden

|  |

iLite

Jung YE, Lee KW, Cho JH, et al | Sci Rep | 2023

Heating-mediated purification of active FGF21 and structure-based design of its variant with enhanced potency

Kinne AS, Tillman EJ, Abdeen SJ, et al | J Pharm Biomed Anal | 2023

Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin

Lallemand, C., Fernando-Miguel, et al | Medical Research Archives | 2023

Analysis of Bevacizumab Activity Following Treatment Patients with Ovarian Cancer or Glioblastoma

Lallemand, C., Fernando-Miguel, et al | Medical Research Archives | 2023

Analysis of Bevacizumab Activity Following Treatment Patients with Ovarian Cancer or Glioblastoma

Guo K, Barrett BS, Morrison JH, et al | Proc Natl Acad Sci U S A | 2022

Interferon resistance of emerging SARS-CoV-2 variants

Guo K, Shen G, Kibbie J, et al | PLoS Pathog | 2022

Qualitative Differences Between the IFNα subtypes and IFNβ Influence Chronic Mucosal HIV-1 Pathogenesis 

Lee CG, Kim T, Hong S, et al | Front Pharmacol | 2021

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing

Kharlamova N, Hermanrud C, Dunn N, et al | Front Immunol | 2020

Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier 

Lallemand C, Ferrando-Miguel R, Auer M, et al | Front Immunol | 2020

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma 

Sjögren J, Lood R, Nägeli A. | Glycobiology | 2020

On enzymatic remodeling of IgG glycosylation; unique tools with broad applications 

Meier S, Bohnacker S, Klose CJ, et al | Nat Commun | 2019

The molecular basis of chaperone-mediated interleukin 23 assembly control 

Mojtahed Poor S, Ulshöfer T, Gabriel LA, et al | Clin Exp Immunol | 2019

Immunogenicity assay development and validation for biological therapy as exemplified by ustekinumab 

Hyun JW, Kim G, Kim Y, et al | J Clin Neurol | 2018

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis 

Lallemand C, Liang F, Staub F, et al | J Immunol Res | 2017

A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies 

Link J, Ramanujam R, Auer M, et al | PLoS One | 2017

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results 

Bachelet D, Hässler S, Mbogning C, et al | PLoS One | 2016

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis 

Hermanrud C, Ryner M, Luft T, Jensen PE, et al | J Immunol Methods | 2016

Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta

Jacobson JM, Bosinger SE, Kang M, et al | AIDS Res Hum Retroviruses | 2016

The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1 AIDS Res Hum Retroviruses

Pogue SL, Taura T, Bi M, et al | PLoS One | 2016

Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity 

van Bezooijen JS, Koch BC, et al | Ther Drug Monit | 2016

Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations

Aalbers CJ, Bevaart L, Loiler S, et al | PLoS One | 2015

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis 

Eng GP, Bendtzen K, Bliddal H, et al | Arthritis | 2015

Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study 

Hermanrud C, Ryner ML, et al |  J Interferon Cytokine Res | 2014

Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point

Mora J, Given Chunyk A, et al | AAPS J | 2014

Next generation ligand binding assays-review of emerging technologies' capabilities to enhance throughput and multiplexing

Cardillo TM, Trisal P, et al | BMC Cancer | 2013

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro 

Hardy GA, Sieg S, Rodriguez B, et al | PLoS One | 2013

Interferon-α is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers

Wadhwa M, Subramanyam M, Goelz S, et al |  J Interferon Cytokine Res | 2013

Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β

Tattermusch S, Skinner JA, Chaussabel D, et al | PLoS Pathog | 2012

Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy

Rossi EA, Rossi DL, Cardillo TM, et al | Blood | 2011

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers 

Rossi EA, Goldenberg DM, et al | Blood | 2009

CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas